Pfizer update

Pfizer announced that in 2015 the are going to start trials that combine imunitherapy (PDL-1 and PD-1) drugs with its two ALK inhibitor drugs.

Pfizer is planning a potential pivotal study of PF-06463922 starting in 2015.

By the end of this year Pfizer expects to have five different immuno-oncology agents in the clinic that may possibly double by end of 2016.

http://www.pfizer.com/system/files/presentation/PFE-Transcript-2015-01-13T22_30_0.pdf

This entry was posted in 3922 - lorlatinib by Pfizer, crizotinib - Xalkori from Pfizer, Imunotherapies. Bookmark the permalink.

Leave a Reply